| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infecti...
 
																	Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of...
 
																	
 
																	
 
																	
 
																	Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generat...
 
																	 
																	Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generat...
 
																	Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $...